Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. The company's drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging two technologies that power a pipeline of high value therapeutics - a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/23/24	$165,000,000	Series A	AbbVie Ventures abrdn BVF Partners Cormorant Asset Management Foresite Capital Freepoint Capital Group Goldman Sachs Hillhouse Investment Janus Henderson Investors Logos Capital Marshall Wace Omega Funds T. Rowe Price Associates Vida Ventures	undisclosed